Haleon has named Nathalie Gerschtein as president North America, following Lisa Paley’s announcement to step down from her role. Gerschtein said, “I am honored to join Haleon at such an ...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...

Pfizer has completing its full exit from Weybridge-headquartered health firm Haleon. Haleon has agreed to an off-market purchase of 44,155,844 ordinary shares of £0.01 each from Pfizer. The off-market ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Haleon plc (NYSE:HLN) British multinational healthcare firm Haleon plc (NYSE:HLN) rose for a second day on Monday, adding 3.93 percent to close at $10.58 apiece as investors cheered its bullish ...

Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today.

US pharmaceutical firm Pfizer (PFE) has sold off its remaining stake in Sensodyne and Panadol maker Haleon (HLN.L) for around £2.5 billion. Haleon has agreed to buy back 44 million shares from Pfizer ...

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a ...